Chang Han - Researcher Profile | RDL Research Database

Publications

2 shown

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann , Tudor‐Eliade Ciuleanu , Adam Płużański +21 more

Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden,...

2018 New England Journal of Medicine 3061 citations

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,566
Institution: Bristol-Myers Squibb (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2285-1247

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.